Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 3: Eight-day randomized clinical trial in the UK


Authored by  A R Tricker, AJ Stewart*, C Martin Leroy, D Lindner, MK Schorp*, R Dempsey

Published in Regulatory Toxicology and Pharmacology     
* This author is not affiliated with PMI.

Abstract

A randomized, controlled, open-label, parallel-group, single-center study to determine biomarkers of exposure to nine selected harmful and potentially harmful constituents (HPHC) in cigarette smoke and urinary excretion of mutagenic material in 160 male and female subjects smoking Marlboro cigarettes (6 mg tar, 0.5 mg nicotine, and 7.0 mg CO) at baseline. Subjects were randomized to continue smoking Marlboro cigarettes, or switch to using an Electrically Heated Cigarette Smoking System (EHCSS) smoking one of two EHCSS series-K cigarettes, the EHCSS-K6 cigarette (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO) or the EHCSS-K3 cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO), or switch to smoking Philip Morris One cigarettes (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO), or to no-smoking. The mean decreases from baseline to Day 8 were statistically significant (p ⩽ 0.05) for all determined HPHC including benzene and CO (the primary objectives), and urinary excretion of mutagenic material in the EHCSS-K6 (range −35.5 ± 29.2% to −79.4 ± 14.6% [mean ± standard deviation]), EHCSS-K3 (range −41.2 ± 26.6% to −83.1 ± 9.2%), and PM1 (range −14.6 ± 24.1% to −39.4 ± 17.5%) groups. The largest reductions in exposure occurred in the no-smoking group (range −55.4 ± 45.0% to −100.0 ± 0.0%).